State Street Health Care Select Sector SPDR ETF

The State Street Health Care Select Sector SPDR ETF seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the Health Care Select Sector Index (the "Index").The Index seeks to provide an effective representation of the health care sector of the S&P 500 Index.Seeks to provide precise exposure to companies in the pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and health care technology industries.Allows investors to take strategic or tactical positions at a more targeted level than traditional style based investing.

State Street Health Care Select Sector SPDR ETF trades as XLV on AMEX. The company is classified in Financial Services / Asset Management and reports in USD.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

State Street Health Care Select Sector SPDR ETF can be compared against peers such as Dimensional - US Core Equity 2 ETF, iShares Core Dividend Growth ETF, State Street SPDR Dow Jones Industrial Average ETF Trust, Schwab U.S. Broad Market ETF, VanEck Semiconductor ETF, Vanguard Small-Cap Growth ETF.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $39.01B, beta of 0.56, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

XLV currently shows total debt of N/A and beta of 0.56. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: N-CSRS (2026-06-04 00:00:00), NPORT-P (2026-05-28 00:00:00), NPORT-P (2026-05-28 00:00:00), NPORT-P (2026-05-28 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ssga.com/us/en/institutional/etfs/state-street-health-care-select-sector-spdr-etf-xlv

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.